Apogee Therapeutics, Inc.
Every calculator, already run for APGE
Open the full toolkit →You have the numbers on APGE. Get the argument.
A written report on which of these readings actually decide the outcome for Apogee Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
15 analysts covering APGEAnalyst Price Target Disagreement for Apogee Therapeutics, Inc.
Wall Street's bull case implies +2% from the current price; the bear case implies -40%. A 42% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial…
APGE — frequently asked
Is APGE a buy right now?
Wall Street's consensus rating on Apogee Therapeutics, Inc. is Hold across 15 analysts, with a mean price target of $130.53 (-3% vs. the current $134.61). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is APGE's next earnings date?
Apogee Therapeutics, Inc. is next scheduled to report earnings around Nov 9, 2026. A full APGE research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Apogee Therapeutics, Inc.?
Analysts covering Apogee Therapeutics, Inc. (APGE) range from a bear-case target of $81.00 to a bull-case high of $137.00, with a mean consensus target of $130.53 across 12 analysts. The spread of $56.00 (42% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Apogee Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Apogee Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full APGE research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Apogee Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.